EVGN - エボジェン （Evogene Ltd.）

By Sabela Ojea Shares of Evogene Ltd. on Wednesday jumped about 22% after the data analysis biotech company said that its subsidiary Biomica Ltd. raised $20…

https://www.investing.com/news/pro/evogene-ltd-pt-lowered-to-1-at-roth-capital-432SI-2964003

LEVERKUSEN (dpa-AFX) - Evogene Ltd. (EVGN) announced that Bayer will pay the company an amount of $3.5 million under their joint seed traits collaboration agreement. The one-time payment is part o…

Evogene (EVGN) announced that Bayer will pay Evogene an amount of $3.5M under their joint seed traits collaboration agreement.Under the collaboration agreement, the company provided…

/PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize…

Evogene''s <> unit Canonic said it shipped the first batch of its unique cannabis varieties to Portugal, after receiving export approval by the Israeli Ministry of Health and

Biomica and a subsidiary of Evogene (EVGN) announce that the Israeli Ministry of Health (MoH) cleared the company to proceed with its Proof-of-Concept ((POC)), Phase I clinical trial

Evogene Ltd (EVGN) shares closed today at 1.9% above its 52 week low of $1.58, giving the company a market cap of $66M. The stock is currently down 1.8% year-to-date, down 68.7% over the past 12 months, and down 68.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 10.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.9. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -75.0% The company's stock price performance over the past 12 months lags the peer average by 110.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Evogene Ltd (EVGN) shares closed today at 1.9% above its 52 week low of $1.60, giving the company a market cap of $67M. The stock is currently down 65.3% year-to-date, down 71.0% over the past 12 months, and down 68.0% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 56.3% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 395.8% The company's stock price performance over the past 12 months lags the peer average by 396.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Geode Capital Management LLC grew its stake in Evogene Ltd. (NASDAQ:EVGN) by 40.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,731 shares of the biotechnology companys stock after purchasing an additional 7,761 shares during the period. Geode Capital Management LLC [] The post Evogene Ltd. (NASDAQ:EVGN) Shares Acquired by Geode Capital Management LLC appeared first on ETF Daily News .

REHOVOT, Israel, Nov. 30, 2021 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), reported today positive results from pre-clinical studies in its IBD program. In

Zacks Investment Research lowered shares of Evogene (NASDAQ:EVGN) from a hold rating to a sell rating in a research note released on Monday, Zacks.com reports. According to Zacks, Evogene is a leading computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. Incorporating a deep understanding []

Evogene (NASDAQ:EVGN) had its price objective trimmed by Royal Bank of Canada from $8.00 to $7.00 in a research report report published on Wednesday morning, Stock Target Advisor reports. The firm currently has an outperform rating on the biotechnology companys stock. EVGN has been the subject of a number of other research reports. Roth Capital []

LPL Financial LLC lifted its holdings in shares of Evogene Ltd. (NASDAQ:EVGN) by 21.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,485 shares of the biotechnology companys stock after purchasing an additional 10,625 shares during the quarter. LPL Financial LLC []

Evogene (NASDAQ:EVGN) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.19) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by ($0.02), MarketWatch Earnings reports. Evogene had a negative net margin of 2,326.70% and a negative return on equity of 38.88%. During the same quarter in the prior year, []